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ORIGINAL RESEARCH
Gut Microbiota- Dependent Trimethylamine 
N- oxide and Cardiovascular Outcomes in 
Patients With Prior Myocardial Infarction: 
A Nested Case Control Study From the 
PEGASUS- TIMI 54 Trial
Baris Gencer, MD*; Xinmin S. Li, PhD*; Yared Gurmu, PhD; Marc P. Bonaca, MD, MPH; David A. Morrow, MD, MPH; 
Marc Cohen, MD; Deepak L. Bhatt, MD, MPH; P. Gabriel Steg, MD; Robert F. Storey, MD; Per Johanson, MD, PhD; 
Zeneng Wang, PhD; Stanley L. Hazen, MD, PhD; Marc S. Sabatine , MD, MPH
BACKGROUND: Trimethylamine N- oxide (TMAO) may have prothrombotic properties. We examined the association of TMAO 
quartiles with major adverse cardiovascular events (MACE) and the effect of TMAO on the efficacy of ticagrelor.
METHODS AND RESULTS: PEGASUS- TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using 
Ticagrelor Compared to Placebo on a Background of Aspirin - Thrombolysis in Myocardial Infarction 54) randomized 
patients with prior myocardial infarction to ticagrelor or placebo (median follow- up 33 months). Baseline plasma concen-
trations of TMAO were measured in a nested case- control study of 597 cases with cardiovascular death, myocardial infarc-
tion, or stroke (MACE) and 1206 controls matched for age, sex, and estimated glomerular filtration rate [eGFR]. Odds ratios 
(OR) were used for the association between TMAO quartiles and MACE, adjusting for baseline clinical characteristics (age, 
sex, eGFR, region, body mass index, hypertension, hypercholesterolemia, diabetes mellitus, smoking, peripheral artery 
disease, index event, aspirin dosage and treatment arm), and cardiovascular biomarkers (hs- TnT [high- sensitivity troponin 
T], hs- CRP [high- sensitivity C- reactive protein], NT- proBNP [N- terminal- pro- B- type natriuretic peptide]). Higher TMAO 
quartiles were associated with risk of MACE (OR for quartile 4 versus quartile 1, 1.43, 95% CI, 1.06–1.93, P trend=0.015). 
The association was driven by cardiovascular death (OR 2.25, 95% CI, 1.28–3.96, P trend=0.003) and stroke (OR 2.68, 
95% CI, 1.39–5.17, P trend<0.001). After adjustment for clinical factors, the association persisted for cardiovascular 
death (ORadj 1.89, 95% CI, 1.03–3.45, P trend=0.027) and stroke (ORadj 2.01, 95% CI, 1.01–4.01, P trend=0.022), but was 
slightly attenuated after adjustment for cardiovascular biomarkers (cardiovascular death: ORadj 1.74, 95% CI, 0.88–3.45, 
P trend=0.079; and stroke: ORadj 1.82, 95% CI, 0.88–3.78, P trend=0.056). The reduction in MACE with ticagrelor was 
consistent across TMAO quartiles (P interaction=0.92).
CONCLUSIONS: Among patients with prior myocardial infarction, higher TMAO levels were associated with cardiovascular death 
and stroke but not with recurrent myocardial infarction. The efficacy of ticagrelor was consistent regardless of TMAO levels.
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I
ntestinal microbiota have been associated with sev-
eral pathways (eg, inflammation, obesity, and dia-
betes mellitus) that affect cardiovascular health.1,2 
Trimethylamine N- oxide (TMAO) is a circulating me-
tabolite produced by gut microbiota involving nu-
trient precursors abundant in the western diet (red 
meat, betaine, choline, carnitine, trimethyllysine),3–5 
and has been associated with incident cardiovas-
cular risk in stable cohorts and patients with acute 
coronary syndromes.6–9 TMAO may have prothrom-
botic properties that are partially reversible with the 
use of aspirin.10 In contrast to the setting of an acute 
coronary syndrome,11 the prognostic value of TMAO 
in stable patients with prior myocardial infarction (MI) 
has not been extensively explored, nor has an inter-
action with long- term use of more potent antiplatelet 
therapy. Currently, there is an unmet medical need 
to identify patients at higher ischemic risk who might 
derive greater benefit from more intensive preventive 
strategies after MI.12,13 This prognostication is espe-
cially important to individualize long- term therapies 
given the variation of residual risk in patients with 
known cardiovascular disease (CVD).14
In the PEGASUS- TIMI 54 trial (Prevention of 
Cardiovascular Events in Patients With Prior Heart 
Attack Using Ticagrelor Compared to Placebo on a 
Background of Aspirin-Thrombolysis in Myocardial 
Infarction 54), patients with a history of MI during the 
preceding 1 to 3 years before randomization were as-
signed to ticagrelor or placebo.15 Our primary aim was 
to determine if baseline plasma TMAO levels were in-
dependently associated with major adverse cardiovas-
cular events (MACE) in stable patients with prior MI. 
Our secondary aim was to determine if plasma TMAO 
levels can identify patients who have a greater risk re-
duction in MACE with prolonged use of ticagrelor after 
an MI.
METHODS
We encourage parties interested in collaboration and 
data sharing to contact the corresponding author di-
rectly for further discussions.
Study Population
The PEGASUS- TIMI 54 trial was a randomized double- 
blind, placebo- controlled trial that tested the cardio-
vascular benefit of prolonged dual antiplatelet therapy 
with the addition of ticagrelor (a P2Y12 receptor antago-
nist) to low- dose aspirin among stable patients with a 
history of MI.16 The trial tested two doses of ticagre-
lor, 90 mg twice daily, a well- established dosage regi-
men in patients with acute coronary syndromes, and 
60 mg twice daily versus placebo in a randomly as-
signed ratio 1:1:1.16 All patients were on a background 
therapy of aspirin 75 to 150 mg daily. The protocol, in-
cluding the biomarker substudy, was approved by the 
relevant ethics committee at each participating site. 
CLINICAL PERSPECTIVE
What Is New?
• In patients with prior myocardial infraction, we 
observed an association between higher tri-
methylamine N-oxide levels and incident car-
diovascular death or stroke events.
• The associations remained significant after ad-
justment for clinical factors but were slightly at-
tenuated with further adjustment for established 
biomarkers.
What Are the Clinical Implications?
• Reconciling previous and current findings, tri-
methylamine N-oxide levels offer insight for risk 
assessment but, at least among patients with 
prior myocardial infarction, do not offer ad-
ditional information for tailoring more intensive 
antiplatelet therapy.
Nonstandard Abbreviations and Acronyms
ACS  acute coronary 
syndromes
CVD cardiovascular disease
eGFR  estimated glomerular 
filtration rate
hs-CRP  high-sensitivity 
C-reactive protein
hs-TnT high-sensitivity troponin T
IQR interquartile ranges
MACE  major adverse  
cardiovascular events
MI myocardial infarction
NT-proBNP  N-terminal-pro-B-type 
natriuretic peptide 
hormone
OR odds ratio
PEGASUS-TIMI 54 trial  Prevention of  
Cardio vas cular Events 
in Patients With Prior 
Heart Attack Using 
Tic agrelor Com pared 
to Placebo on a  
Background of Aspirin- 
Thrombolysis in  
Myo car dial Infarction 54
SD standard deviation
TMAO trimethylamine N-oxide
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Eligible patients were defined by a history of sponta-
neous MI 1 to 3 years before the enrollment, were at 
least 50  years of age, and had one of the following 
additional high- risk features: age of 65 years or older, 
diabetes mellitus requiring medication, a second prior 
spontaneous MI, multivessel coronary artery disease, 
or chronic renal disease, defined as an estimated glo-
merular filtration rate (eGFR) <60 mL per minute per 
1.73 m2 body surface area.15 Briefly, patients were ineli-
gible if they required the use of P2Y12 receptor antago-
nist or anticoagulant therapy during the study period; 
had a history of bleeding disorder, ischemic stroke, 
or intracranial bleeding; or had gastrointestinal bleed-
ing within the previous 6 months or a major surgery 
within the previous 30 days.15 The study protocol was 
approved by local institutional review committees and 
written informed consent was obtained from all par-
ticipants. Among a total of 21 162 patients who under-
went randomization from October 2010 through May 
2013, a biomarker substudy was conducted in 8635 
participants.15
Study Design
We conducted a nested case- control study evaluating 
the association between TMAO levels and risk of MACE 
among participants in the PEGASUS- TIMI 54 trial who 
had a collection of blood sample at the baseline re-
gardless of the randomization arm.15 Within this study, 
eligible cases were men or women who experienced 
the prespecified primary composite end point of car-
diovascular death, MI, or stroke. Eligible controls were 
men or women who remained free from cardiovascu-
lar death, MI, or stroke through the end of follow- up. 
Eligible controls were matched for age (range ±3 years), 
sex, and eGFR (range ±5 mL/min per 1.73 m2) with a 
prespecified ratio of 2 controls for each case. The defi-
nitions for cardiovascular death, MI, and stroke have 
been previously described.15,16 We initially defined 603 
cases and 1206 matched controls (ratio 2:1), but the 
final sample with measurable TMAO concentrations 
yielded 597 cases and 1206 controls (see Table S1 for 
baseline characteristics in the entire PEGASUS- TIMI 54 
trial versus the TMAO nested case- control cohort).
Biomarker Analysis
TMAO concentrations in plasma were quantified using 
stable isotope dilution high- performance liquid chro-
matography with online tandem electrospray ionization 
mass spectrometry (LC/MS/MS) using d9- (trimethyl)- 
labeled internal standard as described previously 
using a Shimadzu Nexera Ultra High Performance 
Liquid Chromatograph (UHPLC) system interfaced 
with Shimadzu 8050 triple quadrupole mass spec-
trometer.7,11,17 Exploratory measurements were also 
done for plasma choline and betaine as potential pre-
cursors of TMAO.4,8,18
Statistical Analysis
For the baseline characteristics according to TMAO 
quartiles, continuous variables are presented as me-
dians with interquartile ranges (IQR) and were com-
pared with Kruskal–Wallis test; categorical variables 
are presented as absolute counts and percentages 
and were compared with chi- square test. We com-
pared values of TMAO between cases and controls 
with P values calculated using Wilcoxon Rank Sum 
tests. We evaluated the correlation between TMAO 
concentrations and the following continuous vari-
ables: age, body mass index (BMI), eGFR, hs- CRP 
(high- sensitivity C- reactive protein), hs- TnT (high- 
sensitivity troponin T), and NT- proBNP (N- terminal 
pro- B- type natriuretic peptide hormone). For our 
primary aim, we performed conditional logistic re-
gression to explore the association between the 
exposure (TMAO quartiles) and the binary outcome 
in 597 cases and 1194 controls matching for age, 
sex, and eGFR regardless of the randomization arm. 
We categorized TMAO in quartiles and compared 
the odds ratio (OR) for the highest quartile versus the 
lowest quartile and assessed the P value for trend 
across categories.11 The trend P value was calcu-
lated by testing the coefficient of an ordinal TMAO 
variable from the logistic regression model. We also 
used TMAO concentrations as a continuous variable 
(standardized by subtracting the mean and dividing 
by the standard deviation) and presented the esti-
mates per increase of one standard deviation (1 SD). 
To evaluate potential confounding factors, we exam-
ined the differences of baseline characteristics across 
TMAO quartiles. We adjusted our conditional logistic 
regression model (primary outcome versus not) for 
baseline CVD clinical risk factors (age, sex, eGFR, 
diabetes mellitus, BMI, hypertension, hypercholes-
terolemia, smoking status, peripheral artery disease), 
region of enrollment, severity of the qualifying index 
events (type of MI), aspirin dosage, and treatment 
arm and made further adjustment for the baseline 
traditional prognostic cardiovascular biomarkers, hs- 
CRP, hs- TnT, and NT-proBNP. These biomarkers have 
been previously shown to predict future MACE in pa-
tients with coronary artery disease.13,19,20 Because 
renal function is a major confounding factor,21 we 
added a subgroup analysis comparing baseline 
eGFR ≥60 mL/min per 1.73 m2 versus eGFR <60 mL/
min per 1.73 m2. We repeated this same process for 
each individual end point of cardiovascular death, MI, 
and stroke using an unmatched logistic regression 
model, including this time the total population of 597 
cases and 1206 controls. For our secondary aim, we 
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investigated whether the effect of ticagrelor on the 
primary end point varied by quartiles of TMAO. The 
interaction P value associated with this test is com-
puted using a likelihood ratio test that compares a 
full model with the main effect terms for TMAO quar-
tiles, treatment, and an interaction effect of TMAO 
by treatment, with a reduce model that had main ef-
fect terms for TMAO and treatment only. The same 
Table 1. Baseline Characteristics Stratified by TMAO Quartile (N=1803)
Variable
1st Quartile N=452 
(0.12–3.24 ƈmol/L)
2nd Quartile N=450 
(3.25–4.75 ƈmol/L)
3rd Quartile N=450 
(4.76–7.20 ƈmol/L)
4th Quartile N=451 
(7.22–157.37 ƈmol/L) P Value
Matched variables
Age, median (IQR) 64 (58, 70) 66 (59, 73) 69 (62, 75) 69 (62, 76) <0.001
Female, n (%) 95 (21.0) 100 (22.2) 115 (25.6) 152 (33.7) <0.001
eGFR, median (IQR) 75.9 (65.8, 88.0) 71.7 (59.4, 81.8) 64.4 (53.5, 75.6) 55.2 (40.6, 70.6) <0.001
Other variables
BMI, median (IQR) 28.3 (25.5, 31.1) 28.2 (25.3, 31.2) 28.4 (25.6, 31.6) 29.9 (26.6, 33.7) <0.001
White race, n (%) 430 (95.1) 434 (96.4) 440 (97.8) 432 (95.8) 0.185
Region 0.049
Eastern Europe, n (%) 160 (35.4) 151 (33.6) 139 (30.9) 134 (29.7)
North America, n (%) 143 (31.6) 151 (33.6) 171 (38.0) 189 (41.9)
Western Europe, n (%) 149 (33.0) 148 (32.9) 140 (31.1) 128 (28.4)
Smoking status, n (%) 0.002
Never 114 (25.2) 141 (31.3) 156 (34.7) 153 (33.9)
Former 226 (50.0) 216 (48.0) 212 (47.2) 231 (51.2)
Current 112 (24.8) 93 (20.7) 81 (18.0) 67 (14.9)
Hypertension, n (%) 339 (75.0) 357 (79.3) 362 (80.4) 388 (86.0) 0.001
Dyslipidemia, n (%) 356 (78.8) 377 (83.8) 375 (83.3) 372 (82.5) 0.19
Diabetes mellitus, n (%) 100 (22.1) 133 (29.6) 155 (34.4) 224 (49.7) <0.001
Multivessel CAD, n (%) 306 (67.7) 283 (62.9) 273 (60.7) 292 (64.7) 0.157
>1 prior MI, n (%) 93 (20.6) 81 (18.0) 92 (20.4) 100 (22.2) 0.48
History of PAD, n (%) 33 (7.3) 42 (9.3) 38 (8.4) 57 (12.6) 0.039
Qualifying event
STEMI, n (%) 229 (50.8) 220 (48.9) 225 (50.0) 172 (38.2) <0.001
NSTEMI, n (%) 207 (45.9) 220 (48.9) 215 (47.8) 257 (57.1) 0.004
Years from event, median (IQR) 1.7 (1.2, 2.3) 1.6 (1.2, 2.2) 1.7 (1.3, 2.3) 1.6 (1.2, 2.2) 0.132
Medications
Aspirin, n (%) 450 (99.6) 450 (100) 449 (99.8) 451 (100) 0.30
Aspirin dosage, median (IQR) 81 (80, 100) 81 (80, 100) 81 (80, 100) 81 (80, 100) 0.008
Aspirin ≥100 mg, n (%) 144 (31.9) 138 (30.8) 171 (38.3) 153 (34.0) 0.090
Statin, n (%) 429 (94.9) 424 (94.2) 426 (94.7) 406 (90.0) 0.008
Beta- blocker, n (%) 385 (85.2) 383 (85.1) 384 (85.3) 395 (87.6) 0.67
ACEI or ARB, n (%) 363 (80.3) 359 (79.8) 358 (79.6) 344 (76.3) 0.44
Placebo, n (%) 159 (35.2) 163 (36.2) 152 (33.8) 140 (31.0) 0.26
Ticagrelor 60 mg bid, n (%) 158 (35.0) 130 (28.9) 153 (34.0) 151 (33.5)
Ticagrelor 90 mg bid, n (%) 135 (29.9) 157 (34.9) 145 (32.2) 160 (35.5)
Biomarker measurement
hs- TnT (ng/L) (median, IQR) 6.9 (4.3, 11.1) 8.0 (5.3, 12.8) 9.3 (5.8, 15.6) 12.3 (7.3, 22.5) <0.001
NT- proBNP (pg/mL) (median, 
IQR)
131.3 (69.3, 291.2) 163.3 (77.0, 352.3) 181.0 (81.1, 463.0) 276.9 (116.1, 619.1) <0.001
hs- CRP (mg/dL) (median, IQR) 1.5 (0.7, 3.2) 1.6 (0.7, 3.5) 1.5 (0.8, 3.3) 2.0 (0.9, 4.2) 0.003
Continuous variables are presented as medians with interquartile ranges (IQR) and were compared with Kruskal–Wallis test. Categorical variables are 
presented as absolute counts and percentages and were compared with chi- square test. ACEI indicates angiotensin- converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; hs- CRP, high- sensitivity 
C- reactive protein; hs- TnT, high- sensitivity troponin T; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non–ST- segment–elevation myocardial 
infarction; NT- proBNP, N- terminal- proB- type natriuretic peptide; PAD, peripheral artery disease; STEMI, ST- segment–elevation myocardial infarction; and 
TMAO, trimethylamine N- oxide.
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analysis plans were applied for choline and betaine. 
A P<0.05 was considered significant for all analyses.
RESULTS
Baseline Characteristics
Baseline characteristics of the patients, overall and 
stratified by the quartiles of plasma TMAO quartiles, 
are shown in Table 1. Patients with higher TMAO quar-
tiles compared to those with lower TMAO quartiles 
were more likely to be older, female, and had higher 
BMI, and more frequently had comorbidities including 
a history of hypertension, diabetes mellitus, impaired 
renal function, and peripheral artery disease but were 
less likely to be current smokers (Table 1). TMAO con-
centrations were moderately negatively correlated with 
eGFR (r=−0.41, P<0.001) and weakly positively corre-
lated with hs- TNT (r=0.29, P<0.001) and NT- proBNP 
(r=0.20, P<0.001) (Table S2).
The Association of TMAO Quartiles With 
Major Adverse Cardiovascular Events
The TMAO concentrations were borderline statisti-
cally significantly different between MACE cases 
and controls, with significant differences between 
cardiovascular death cases and controls, as well as 
between stroke cases and controls, whereas no sig-
nificant differences were found for recurrent MI cases 
and controls (Figure 1). When analyzed as quartiles, 
as compared with patients in the first quartile (Q1) of 
TMAO, the risk for the primary end point of cardio-
vascular death, MI, or stroke was significantly higher 
in patients in the highest quartile (Q4) of TMAO using 
conditional logistic regression (OR for Q4 versus Q1 
1.43, 95% CI, 1.06–1.93, P for trend across quar-
tiles=0.015, Table  2). The association was primarily 
driven by cardiovascular death (Q4 OR 2.25, 95% CI, 
1.28–3.96, P trend=0.003) and stroke (Q4 OR 2.68, 
95% CI, 1.39–5.17, P trend<0.001). The association 
with MACE was attenuated after adjustment for clini-
cal factors including age, sex, eGFR, hypertension, 
hypercholesterolemia, diabetes mellitus, peripheral ar-
tery disease, qualifying index event, smoking, region, 
BMI, aspirin dosage, and treatment arm (adjusted OR 
1.27, 95% 0.92–1.75, P for trend=0.10) and further 
adjustment for other biomarkers (hs- TnT, NT- proBNP 
and hs- CRP) (adjusted OR 1.22, 95% CI, 0.86–
1.74, P for trend=0.20). After adjustment for clini-
cal factors, the association remained significant for 
Figure 1. TMAO concentrations comparing cases vs controls for MACE, cardiovascular death, 
recurrent MI, and stroke events.
The P values were obtained using Wilcoxon ranking test. Values beyond the 99% percentile are not 
graphed to avoid an excessive y axis. CV indicates cardiovascular; MACE, major adverse cardiovascular 
events; MI, myocardial infarction; and TMAO, trimethylamine N- oxide.
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cardiovascular death (adjusted OR 1.89, 95% CI, 
1.03–3.45, P  trend=0.027) and stroke (adjusted OR 
2.01, 95% CI<1.01–4.01, P trend=0.022, Figure 2) but 
was slightly attenuated after further adjustment for 
biomarkers (adjusted OR fourth versus lowest quar-
tiles for cardiovascular death 1.74, 95% CI, 0.88–3.45, 
P for trend=0.079; adjusted OR for stroke 1.82, 95% 
CI, 0.88–3.78, P for trend=0.056). We did not find an 
association between TMAO quartiles and risk of re-
current MI events, even when modeled as a continu-
ous variable (Table S3). We did not find a significant 
interaction by baseline renal function, although the as-
sociations tended to be stronger for those with eGFR 
≥60  mL/min per 1.73  m² compared with those who 
had an eGFR <60 mL/min per 1.73 m² after adjust-
ment for clinical variables (Table S4). The increased 
risk association with TMAO quartiles was consistent 
regardless the randomization arm (pooled ticagrelor 
versus placebo, Table S5). Neither plasma choline nor 
betaine was significantly associated with MACE after 
adjustment for clinical factors (Table S6).
Ticagrelor Efficacy in the Relation to 
TMAO Quartiles
The efficacy signal of ticagrelor was similar across 
plasma TMAO quartiles (Q1 to Q4) (adjusted P interac-
tion=0.92, Figure  3), and the effect of ticagrelor was 
generally consistent for each individual end point (car-
diovascular death, MI, or stroke) regardless of baseline 
TMAO quartiles (Figure S1).
DISCUSSION
In this analysis from the PEGASUS- TIMI 54 trial, pa-
tients with prior MI who had higher plasma TMAO 
were more likely to experience subsequent cardio-
vascular death or stroke. The associations between 
TMAO and cardiovascular death or stroke remained 
significant after adjustment for clinical factors but 
were slightly attenuated with further adjustment for 
established biomarkers, with the ORs remaining large 
but the lower bound of the 95% CIs crossing 1. The 
associations tended to be stronger for patients with 
normal renal function compared with those who had 
an eGFR <60  mL/min per 1.73  m2. Nonsignificant 
association was noted for TMAO quartiles and re-
current MI events. The efficacy of ticagrelor on the 
primary efficacy end point was consistent regardless 
of baseline TMAO quartile. We did not observe any 
statistically significant association between plasma 
choline or betaine and risks of MACE.18
Few studies reported an association between 
TMAO levels and the mechanisms of stroke events. 
Among 1244 hypertensive patients in China, a 
nested- case control study suggested an association 
between higher TMAO levels and first stroke event, 
especially with respect to hemorrhagic stroke.22 In 
another cohort study of 268 patients who under-
went carotid stenting, increased TMAO levels were 
associated with an increased risk of new ischemic 
brain lesion on cerebral imaging after stenting.23 To 
explore the potential etiology of stroke, two large 
Table 2. Risk of Cardiovascular Events by TMAO Quartiles
TMAO Quartiles Definition
1st Quartile (N=452) 
(Range 
0.12–3.24 ƈmol/L)
2nd Quartile (N=450) 
(Range 
3.25–4.75 ƈmol/L)
3rd Quartile (N=450) 
(Range 
4.76–7.20 ƈmol/L)
4th Quartile (N=451) 
(Range 
7.22–157.37 ƈmol/L)
P for 
Trend
Odds ratios for primary end point (cardiovascular death, MI, and stroke)
Number of cases (%) 138 (30.5) 141 (31.3) 152 (33.8) 166 (36.8)
Matched* Ref 1.03 (0.78–1.37, P=0.81) 1.19 (0.89–1.59, P=0.24) 1.43 (1.06–1.93, P=0.02) 0.015
Odds ratios for cardiovascular death
Number of cases (%) 23 (5.1) 30 (6.7) 38 (8.4) 48 (10.6)
Adjustment for matching 
variable†
Ref 1.32 (0.75–2.34, P=0.34) 1.68 (0.97–2.93, P=0.067) 2.25 (1.28–3.96, P=0.005) 0.003
Odds ratios for recurrent MI
Number of cases (%) 108 (23.9) 101 (22.4) 101 (22.4) 102 (22.6)
Adjustment for matching 
variable†
Ref 0.94 (0.68–1.30, P=0.70) 1.09 (0.79–1.51, P=0.60) 1.10 (0.79–1.55, P=0.57) 0.42
Odds ratios for stroke
Number of cases (%) 15 (3.3) 19 (4.2) 31 (6.9) 41 (9.1)
Adjustment for matching 
variable†
Ref 1.25 (0.62–2.52, P=0.52) 2.05 (1.07–3.93, P=0.031) 2.68 (1.39–5.17, P=0.003) <0.001
The trend P value was calculated by testing the coefficient of an ordinal TMAO variable from the logistic regression model. eGFR indicates estimated 
glomerular filtration rate; MI, myocardial infarction; and TMAO, trimethylamine N- oxide.
*Conditional (matched) logistic regression was used for the primary end point with matching variables (age, sex, eGFR).
†Unconditional (unmatched) logistic regression was used for each individual component cardiovascular death, MI, and stroke events adjusting for matching 
variables (age, sex, eGFR).
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observational studies, together including more than 
6900 elderly participants, showed an increased risk 
of incident atrial fibrillation among those with higher 
TMAO levels even after adjustment for traditional 
confounding clinical factors.24 The available findings 
rather support a possible risk modulation of stroke 
with TMAO levels, but the evidence is low and more 
studies are needed to clarify the mechanisms.
As expected, patients with higher TMAO concen-
trations were more likely to have renal dysfunction. 
There is existing evidence that TMAO may be involved 
in the process of chronic kidney disease and that renal 
dysfunction may lead to higher circulating plasma 
concentrations of TMAO.6 In subgroup analyses by 
baseline eGFR function, we found that the association 
of TMAO tended to be greater in those with normal 
renal function.
The prothrombotic properties described with TMAO 
in previous studies and the possible response to aspirin 
led us to investigate specifically this microbiota marker 
in the PEGASUS- TIMI 54 trial.10,25 Our data show that 
the clinical efficacy of ticagrelor is preserved regardless 
of TMAO levels. Reconciling previous and current find-
ings, TMAO levels offer insight for risk assessment but, 
at least among patients with prior MI, do not offer addi-
tional information for tailoring more intensive antiplatelet 
therapy. The absence of an association with MI in our 
analysis does not support the role of TMAO as a pure 
Figure 2. Risks of cardiovascular death, myocardial infarction, and stroke by TMAO quartiles adjusted for clinical variables 
(black) and biomarkers (red).
MACE was defined as a composite of cardiovascular death, myocardial infarction, and stroke. In the clinical variable model (black), the 
ORs were adjusted for age, sex, estimated glomerular filtration rate, hypertension, hypercholesterolemia, diabetes mellitus, peripheral 
artery disease, qualifying index event, smoking, region, BMI, aspirin dosage, and treatment arm. In the clinical and biomarkers mode 
(red), further adjustment was done for hs-CRP (high- sensitive C- reactive protein), hs-TnT (high-sensitivity troponin T); and NT-proBNP 
(N- terminal- pro hormone BNP). The trend P value was calculated by testing the coefficient of an ordinal TMAO variable from the 
logistic regression model. MACE indicates major adverse cardiovascular events; OR, odds ratio; and TMAO, trimethylamine N- oxide.
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specific marker of atherothrombotic risks. Some of the 
prior associations between TMAO and MI might have 
reflected TMAO’s association with multiple cardiovas-
cular comorbidities including age, hypertension, dyslip-
idemia, diabetes mellitus, and renal dysfunction.
Limitations
Our study findings are applicable just to a secondary 
prevention population with previous MI and treated 
with aspirin. However, a previous cohort of patients 
undergoing elective coronary angiography reported 
a value of 6.2 ƈmol/L corresponding approximately to 
the 75th percentile,1 which is not dissimilar to our 75th 
percentile (7.22 ƈmol/L). Finally, we did not collect data 
on nutritional habits or use of antibiotics prior to blood 
sampling (as a potential unmeasured confounding fac-
tor associated with TMAO levels).
CONCLUSIONS
Among patients with prior MI, higher systemic TMAO 
levels were associated with higher risk of cardio-
vascular death and stroke after adjusting for clinical 
factors but not with recurrent MI. The efficacy of tica-
grelor on cardiovascular outcomes was consistent 
regardless of baseline TMAO levels.
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Table S1. Baseline characteristics of the full PEGASUS-TIMI 54 trial vs. the TMAO Nested Case-
Control Cohort. 
Variable Entire Trial (N=21,162) TMAO Nested Case-Control Cohort (N=1,803) 
Matched variables   
Age (median, IQR) 65 (59, 71) 67.9 (59.5, 74) 
Female (n, %) 5,050 (23.9) 462 (25.6) 
eGFR (median, IQR) 72.4 (61.0, 84.0) 68.2 (55.0, 79.8) 
Other variables   
BMI (median, IQR) 27.8 (25.2, 31.2) 28.7 (25.7, 32.0) 
White race (n, %) 18,327 (86.6) 1,736 (96.3) 
Region   
Eastern Europe (n, %) 6,290 (29.7) 584 (32.4) 
North America (n, %) 3,907 (18.5) 654 (36.3) 
Western Europe (n, %) 6,138 (29.0) 565 (31.3) 
Asia/Pacific 2,369 (11.2) 0 (0) 
South America 2,458 (11.6) 0 (0) 
Current smoking (n, %) 3,536 (16.7) 353 (19.6) 
Hypertension (n, %) 16,407 (77.5) 1,480 (80.2) 
Dyslipidemia (n, %) 16,241 (76.8) 1,480 (82.1) 
Diabetes mellitus (n, %) 6,806 (32.2) 612 (33.9) 
Multivessel CAD (n, %) 12,558 (59.4) 1,154 (64.0) 
> 1 Prior MI (n, %) 3,499 (16.5) 366 (20.3) 
History of PAD (n, %) 1,143 (5.4) 170 (9.4) 
Qualifying event   
STEMI (n, %) 11,329 (53.6) 846 (47.0) 
NSTEMI (n, %) 8583 (40.6) 899 (49.9) 
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ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, 
coronary artery disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial 
infarction; NSTEMI, Non-ST-elevation myocardial infarction; PAD, peripheral artery disease; STEMI, ST-elevation 
myocardial infarction; TMAO, Trimethylamine N-oxide 
 
 
 
 
 
 
 
 
 
 
 
 
Years from event (median, 
IQR) 
1.7 (1.2, 2.3) 1.7 (1.2, 2.3) 
Medications   
Aspirin (n, %) 21,132 (99.9) 1800 (99.8) 
Statin (n, %) 19,604 (92.6) 1,685 (93.5) 
Beta-blocker (n, %) 17,486 (82.6) 1,547 (85.8) 
ACEI or ARB (n, %) 17,030 (80.5) 1424 (79.0) 
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Table S2. Spearman Correlation Between TMAO and Cardiovascular Markers. 
 
 TMAO Betaine Choline 
TMAO (µM) 1.00 -0.03 (P=0.29) 0.26 (P<0.001) 
Betaine (µM) -0.03 (P=0.29) 1.00 0.35 (P<0.001) 
Choline (µM) 0.26 (P<0.001) 0.35 (P<0.001) 1.00 
    
Age (years) 0.21 (P<0.001) 0.07 (P=0.004) 0.19 (P<0.001) 
Weight (kgs) 0.05 (P=0.044) -0.16 (P<0.001) 0.02 (P=0.47) 
eGFR(ml/min/1.73m²) -0.41 (P<0.001) 0.04 (P=0.11) -0.30 (P<0.001) 
BMI (mg/m²) 0.11 (P<0.001) -0.19 (P<0.001) 0.07 (P=0.002) 
Hs-TnT (ng/L) 0.29 (P<0.001) 0.04 (P=0.061) 0.25 (P<0.001) 
NT-pro BNP (ng/mL) 0.20 (P<0.001) 0.12 (P<0.001) 0.18 (P<0.001) 
Hs-CRP (mg/dL) 0.08 (P<0.001) -0.06 (P=0.020) 0.10 (P<0.001) 
 
BMI, body mass index; eGFR, estimates glomerular filtration; Hs-CRP, high sensitive C-reactive protein; Hs-TnT, 
high sensitive Troponin T; MI, myocardial infarction: NT-pro BNP, N-terminal pro B-type natriuretic peptide; 
TMAO, trimethylamine N-oxide. All biomarkers were log-transformed for this analysis. 
 
 
D
ow
nloaded from
 http://ahajournals.org by on June 12, 2020
  
Table S3. Risk of Cardiovascular Events by 1-SD Log-Transformed TMAO Increase. 
Odds Ratios for Primary Endpoint (CV death, MI and Stroke) by 1-SD Log-Transformed TMAO Increase 
 OR (95% CI) 
Matched *  1.09 (0.98-1.21, P=0.12) 
Matched with clinical adjustment # 1.05 (0.93-1.18, P=0.43) 
0DWFKHGZLWKFOLQLFDODQGELRPDUNHUDGMXVWPHQWۅ 1.05 (0.92-1.19, P=0.47) 
Odds Ratios for CV Death by 1-SD Log-Transformed TMAO Increase 
Matching variable adjustment ¶ 1.22 (1.01-1.48, P=0.035) 
Multivariate clinical adjustment § 1.13 (0.92-1.39, P=0.24) 
Multivariate with clinical and biomarker DGMXVWPHQW 1.07 (0.85-1.34, P=0.58) 
Odds Ratios for MI by 1-SD Log-Transformed TMAO Increase 
Matching variable adjustment ¶ 1.04 (0.92-1.18, P=0.51) 
Multivariate clinical adjustment § 0.99 (0.87-1.12, P=0.86) 
Multivariate with clinical and biomarker DGMXVWPHQW 0.94 (0.83-1.08, P=0.38) 
Odds Ratios for Stroke by 1-SD Log-Transformed TMAO Increase 
Matching variable adjustment ¶ 1.25 (1.01-1.53, P=0.038) 
Multivariate clinical adjustment § 1.11 (0.88-1.39, P=0.38) 
Multivariate with clinical and ELRPDUNHUDGMXVWPHQW 1.10 (0.87-1.39, P=0.44) 
* Conditional (matched) logistic regression was used for the primary endpoint with matching variables (age, sex, 
eGFR).  # In addition to matching variables (age, sex and eGFR), further adjustment was performed for the following 
clinical variables: hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index 
event, smoking, region, body mass index, aspirin dosage and treatment arm. ŒIn addition to matching and clinical 
variables, further adjustment was done for log-transformed biomarkers (hs-TnT, NT-proBNP and hs-CRP). 
¶ Unconditional (unmatched) logistic regression was used for each individual component CV death, MI and stroke 
events. § Multivariable adjustment (unmatched) was performed for the following clinical variables: age, sex, eGFR, 
hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index event, smoking, 
region, body mass index aspirin dosage and treatment arm. ,QDGGLWLRQWRPXOWLYDULDWHFOLQLFDOYDULDEOHVDGMXVWPHQW
further adjustment was done for log-transformed biomarkers (hs-TnT, NT-proBNP and hs-CRP). 
CV, Cardiovascular; eGFR, estimated glomerular filtration rate; MI, myocardial infarction: TMAO, Trimethylamine 
N-oxide. 
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Table S4. Risk of Cardiovascular Events by TMAO Quartiles and H*)56WDWXVYV
ml/min/1.73m²). 
Adjusted Odds Ratios for Primary Endpoint (CV death, MI and Stroke) by TMAO Quartiles * 
 2nd Quartile 3rd Quartile 4th Quartile 
H*)5 1.77 (0.81-3.84) 2.03(0.96-4.28) 2.14 (1.04-4.40) 
eGFR < 60  0.94 (0.68-1.30) 1.07 (0.77-1.50) 0.99 (0.68-1.46) 
P for overall interaction = 0.29 
Adjusted Odds Ratios for CV Death by TMAO Quartiles ¶ 
H*)5 3.22 (0.67-15.39) 1.83 (0.38-8.81) 3.17 (0.71-14.05) 
eGFR < 60  0.99 (0.50-1.96) 1.95 (1.05-3.64) 1.31 (0.63-2.73) 
P for overall interaction = 0.097 
Adjusted Odds Ratios for MI by TMAO Quartiles ¶ 
H*)5 1.61 (0.66-3.96) 1.93 (0.83-4.52) 1.52 (0.66-3.48) 
eGFR < 60  0.87 (0.61-1.25) 0.93 (0.64-1.36) 0.95 (0.63-1.46) 
P for overall interaction = 0.44 
Adjusted Odds Ratios for Stroke by TMAO Quartiles ¶ 
H*)5 0.97 (0.17-5.57) 2.39 (0.52-11.09)  2.23 (0.50-10.04) 
eGFR < 60  1.32 (0.61-2.85) 1.76 (0.82-3.77) 2.22 (1.01-4.87) 
P for overall interaction = 0.84 
CV, Cardiovascular disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction: TMAO, 
Trimethylamine N-oxide.  
* Conditional (matched) logistic regression was used for the primary endpoint with matching variables (age, sex, 
eGFR).  In addition to matching variables (age, sex and eGFR), further adjustment was performed for the following 
clinical variables: hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index 
event, smoking, region, body mass index, aspirin dosage and treatment arm. 
¶Multivariable adjustment (unmatched) was performed for the following clinical variables: age, sex, eGFR, 
hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index event, smoking, 
region, body mass index, aspirin dosage and treatment arm.  
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Table S5. Risk of Cardiovascular Events by TMAO Quartiles and Antiplatelet Regimen. 
Odds Ratios for Primary Endpoint (CV death, MI and Stroke) by TMAO Quartiles 
 2nd Quartile 3rd Quartile 4th Quartile 
Placebo 1.05 (0.47-2.37) 1.23 (0.49-3.09) 1.56 (0.60-4.02) 
Pooled Ticagrelor 0.92 (0.59-1.44) 1.09 (0.71-1.68) 1.18 (0.75-1.87) 
P for overall interaction = 0.952 
Odds Ratios for CV Death by TMAO Quartiles § 
Placebo 1.06 (0.41-2.72)  1.22(0.49-3.02) 1.31 (0.51-3.36) 
Pooled Ticagrelor 1.55 (0.73-3.28) 2.17 (1.04-453) 2.34 (1.12-4.89) 
P for overall interaction = 0.742 
Odds Ratios for MI by TMAO Quartiles § 
Placebo 1.06 (0.62-1.79) 0.83 (0.48-1.45) 0.99 (0.56-1.74) 
Pooled Ticagrelor 0.88 (0.58-1.34) 1.23 (0.82-1.86) 0.99 (0.65-1.52) 
P for overall interaction = 0.399 
Odds Ratios for Stroke by TMAO Quartiles § 
Placebo 1.12 (0.32-3.85) 2.36 (0.79-7.04)  2.28 (0.74-7.00) 
Pooled Ticagrelor 1.24 (0.538-2.93) 1.65 (0.72--3.74) 1.91 (0.85-4.32) 
P for overall interaction = 0.895 
# In addition to matching variables (age, sex and eGFR), further adjustment was performed for the following 
clinical variables: hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index 
event, smoking, region, body mass index, aspirin dosage and treatment arm. 
§ Multivariable adjustment (unmatched) was performed for the following clinical variables: age, sex, eGFR, 
hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index event, smoking, 
region, body mass index, aspirin dosage and treatment arm. 
CV, Cardiovascular disease; MI, myocardial infarction: TMAO, Trimethylamine N-oxide.  
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Table S6. Risk of Cardiovascular Events by Choline and Betaine Quartiles. 
Odds Ratios for Primary Endpoint (CV death, MI and Stroke) #  
 2nd Quartile 3rd Quartile 4th Quartile P for trend 
Choline 1.03 (0.77-1.39) 1.28 (0.95-1.72) 1.06 (0.78-1.44) P=0.43 
Betaine 0.78 (0.58-1.04) 0.75 (0.56-1.01) 0.81 (0.60-1.09) P=0.16 
Odds Ratios for CV Death § P for trend 
Choline 0.81 (0.47-1.39)  1.04 (0.61-1.76) 0.64 (0.37-1.13) P=0.24 
Betaine 0.78 (0.47-1.31) 0.76 (0.44-1.32) 1.24 (0.75-2.06) P=0.41 
Odds Ratios for MI § P for trend 
Choline 1.07 (0.77-1.49) 1.33 (0.95-1.85) 1.15 (0.81-1.62) P=0.25 
Betaine 0.82 (0.60-1.13) 0.80 (0.58-1.10) 0.77 (0.55-1.08) P=0.13 
Odds Ratios for Stroke § P for trend 
Choline 0.98 (0.53-1.81) 1.22 (0.67-2.20)  0.82 (0.44-1.56) P=0.71 
Betaine 0.71 (0.40-1.26) 0.83 (0.47-1.47) 0.89 (0.50-1.59) P=0.79 
# In addition to matching variables (age, sex and eGFR), further adjustment was performed for the following clinical variables: 
hypertension, hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index event, smoking, region, body mass index, 
aspirin dosage and treatment arm.  
§ Multivariable adjustment (unmatched) was performed for the following clinical variables: age, sex, eGFR, hypertension, 
hypercholesterolemia, diabetes mellitus, peripheral artery disease, qualifying index event, smoking, region, body mass index, aspirin 
dosage and treatment arm. 
CV, Cardiovascular disease; MI, myocardial infarction. 
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Figure S1. Treatment Effect of Ticagrelor Versus Placebo on the Composite and Individual 
Endpoints of CV Death, MI and Stroke By TMAO Quartiles.  
 
 
CI, confidence intervals; CV, Cardiovascular disease; MI, myocardial infarction; OR, odds ratio; TMAO, 
Trimethylamine N-oxide.  
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